Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 183 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05099315Recruiting
Gut microbiome study in adults with severe eczema
This trial studies the gut microbiome in people with moderate to severe atopic dermatitis (eczema) who are starting or already receiving systemic (whole-body) treatment. It may help researchers understand what changes in gut bacteria are linked to eczema and to treatment response.
Berlin, State of BerlinAges 18 years+ - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Birmingham, AlabamaAges 12 years+ - NCT06996327Recruiting
How ultra-processed foods affect eczema in children
This study looks at whether compounds from ultra-processed foods (like packaged snacks and sodas) contribute to eczema (atopic dermatitis) in children. Researchers will compare children with eczema to healthy children of the same age and sex.
NaplesAges 6 months–10 years - NCT07014007Recruiting
Testing a new moisturizer for eczema in different age groups
This study tests a new moisturizing product (RV4421B) for people with mild to moderate atopic dermatitis (eczema). Participants will use the product along with their usual steroid cream for 12 weeks to see how well it works and if it’s safe for different ages, from babies to adults.
Quatre Bornes, MauritiusAges 3 months+ - NCT07444801Recruiting
Tralokinumab for eczema with genital symptoms
This trial tests if tralokinumab, a drug already approved for moderate-to-severe eczema, helps people who also have eczema in the genital area. It aims to understand how well the drug works for this specific symptom.
Augsburg, MünchenAges 18 years+ - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT03057860Recruiting
Registry study for moderate to severe atopic dermatitis in Germany
This study is a national registry that collects information from people with moderate-to-severe atopic dermatitis (eczema). It helps doctors understand what treatments are used and how patients are doing over time.
Hanover, Lower SaxonyAges Any age - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Fountain Valley, CaliforniaAges 12 years+ - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
The Bronx, New YorkAges 12 years+ - NCT03936335Recruiting
Study women with atopic dermatitis during pregnancy
This is an observational study that looks back at medical and pharmacy records of women with atopic dermatitis around pregnancy. It may help researchers better understand how this condition affects pregnant patients and pregnancy-related care.
Boston, MassachusettsAges 18–49 - NCT05098821Recruiting
Study factors that affect eczema control on dupilumab
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
BerlinAges 18–75 - NCT06937788Recruiting
Atopic dermatitis trial using existing registry data
This trial looks at how well two eczema treatments work by using data from a patient registry. It may help people with moderate to severe eczema who have had symptoms for at least 3 years.
Dresden, SaxonyAges 18 years+ - NCT06158490Enrolling by invitationPhase 2
JYP0061 tablet for moderate to severe eczema
This trial tests a new tablet called JYP0061 for people with moderate to severe atopic dermatitis (eczema) that has lasted at least a year. It aims to see if the drug is safe and effective in reducing symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT07259343Recruiting
Cream with milk peptide for children's mild eczema
This trial tests if a special cream made with a milk protein peptide can improve mild eczema symptoms like itching and reduce bacteria on the skin in children aged 2 to 12.
Aguascalientes, AguascalientesAges 2–12 - NCT07560618RecruitingPhase 4
Testing a new cream for itch relief in atopic dermatitis
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Sacramento, CaliforniaAges 12 years+ - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06238765Recruiting
Adolescent Eczema Drug Safety Registry
This registry tracks the safety and effectiveness of medications used for moderate to severe atopic dermatitis (eczema) in adolescents aged 10 to 15. It helps doctors understand how well these treatments work and what side effects might occur over time.
Waltham, MassachusettsAges 10–15 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Birmingham, AlabamaAges 12 years+ - NCT06300697Recruiting
Food allergy and eczema study at University of Michigan
This study looks at how food allergies and eczema (atopic dermatitis) are related. You will have an oral food challenge (eating a small amount of a possible allergen in a safe setting) and give blood and skin samples to help researchers learn more.
Ann Arbor, MichiganAges 10–55 - NCT06524635RecruitingPhase 2
Study of lutikizumab for hidradenitis suppurativa or eczema
This study tests an investigational medicine called lutikizumab, given as shots under the skin, for people with moderate-to-severe hidradenitis suppurativa (HS) or atopic dermatitis (eczema). It looks at how the medicine affects skin changes and may help if other treatments haven’t worked.
Sacramento, CaliforniaAges 18–75 - NCT06801821Recruiting
Stigma study on skin conditions
This study looks at how people view those with certain skin conditions. It aims to understand stigma, which may help improve awareness and support.
Roma, ItaliaAges 18 years+
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 183 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.